CONTRACEPTIVE COMPOSITIONS WITH REDUCED ADVERSE EFFECTS
VE6142021000077SUndetermined Publication Date: 2022-02-17ESTETRA SRL
0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- VE · VE
- Patent Type
- Designs
- Current Assignee / Owner
- ESTETRA SRL
- Filing Date
- 2021-04-15
- Publication Date
- 2022-02-17
Need to check novelty before this filing date? Find Prior Art
Description
The present invention relates to a combined oral contraceptive with a reduced risk of side effects, including a reduced risk of QT interval prolongation, a reduced risk of decreased testosterone, and a reduced risk of elevated C-reactive protein levels, compared to other combined oral contraceptives. The Estetrol / Drosspirenone combined oral contraceptive described herein exhibits favorable pharmacokinetics for the progestin component. The use of a specific estrogenic component in the combined oral contraceptive carries multiple benefits compared to currently available combined oral contraceptives.